DGIdb - VERAPAMIL Drug Record

VERAPAMIL chembl:CHEMBL6966 ApprovedAntineoplastic

Alternate Names:

VERAPAMIL
VERELAN
CP-165331
NSC-272306NA
CP-16533-1
TARKA
ISOPTIN
D-365
COVERA-HS
IPROVERATRIL
CALAN
VERAPAMILO
SECURON®
CP-165331 / CP-16533-1
ANSYR®
VERAPAMILUM
VÉRAPAMIL
pubchem.compound:2520
rxcui:11170
drugbank:00661
chemidplus:52-53-9
chembl:CHEMBL6966

Drug Info:

Drug Class	anti-arrhythmia agents
Year of Approval	1981
Drug Categories	selective calcium channel blockers with direct cardiac effects
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antihypertensive agent
Drug Categories	ace inhibitors and calcium channel blockers
Drug Categories	adrenergic alpha-1 receptor antagonists
Drug Categories	adrenergic alpha-antagonists
Drug Categories	adrenergic antagonists
Drug Categories	antiarrhythmic agents
Drug Categories	antihypertensive agents
Drug Categories	antihypertensive agents indicated for hypertension
Drug Categories	cytochrome p-450 cyp2c18 substrates
Drug Categories	cytochrome p-450 cyp2c8 inhibitors
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (weak)
Drug Categories	cytochrome p-450 cyp2d6 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2e1 substrates
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a5 inhibitors
Drug Categories	cytochrome p-450 cyp3a5 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp3a5 substrates
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs that are mainly renally excreted
Drug Categories	mate 1 inhibitors
Drug Categories	mate 2 inhibitors
Drug Categories	mate inhibitors
Drug Categories	miscellaneous calcium-channel blocking agents
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	oct1 inhibitors
Drug Categories	oct1 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates
Drug Categories	vasodilating agents
Drug Categories	verapamil and analogues

(6 More Sources)

Publications:

Patel et al., 2005, Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells., Br. J. Pharmacol.
Tfelt-Hansen et al., 2009, Verapamil for cluster headache. Clinical pharmacology and possible mode of action., Headache
Morel et al., 1998, The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits., Br. J. Pharmacol.
Beitelshees AL et al., 2009, CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response., Circ Cardiovasc Genet
Dilmac et al., 2004, Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2., Mol. Pharmacol.
Bacon et al., 1989, Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists., Biochem. Biophys. Res. Commun.
Xu et al., 2008, Effect of amiodarone on Kv1.4 channel C-type inactivation: comparison of its effects with those induced by propafenone and verapamil., Pharmazie
van Noord C et al., 2009, Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation., Pharmacogenet Genomics
Brown et al., 1986, The effects of some slow channel blocking drugs on high affinity serotonin uptake by rat brain synaptosomes., Eur. J. Pharmacol.
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Dahllöf et al., Characterization of multidrug resistance in SEWA mouse tumor cells: increased glutathione transferase activity and reversal of resistance with verapamil., Anticancer Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Ninomiya T et al., 2003, Verapamil, a Ca2+ entry blocker, targets the pore-forming subunit of cardiac type KATP channel (Kir6.2)., J Cardiovasc Pharmacol
Shigeto et al., 2007, Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum., J. Pharmacol. Exp. Ther.
Yamada et al., 2006, Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant., J. Physiol. (Lond.)
Aguirre Ghiso et al., 1998, Secretion of urokinase and metalloproteinase-9 induced by staurosporine is dependent on a tyrosine kinase pathway in mammary tumor cells., Int. J. Cancer
Freeze et al., 2006, State-dependent verapamil block of the cloned human Ca(v)3.1 T-type Ca(2+) channel., Mol. Pharmacol.
Bergson P et al., 2011, Verapamil block of T-type calcium channels., Mol Pharmacol
Shchepotin et al., Apoptosis induced by hyperthermia and verapamil in vitro in a human colon cancer cell line., Int J Hyperthermia
Gong Y et al., 2015, PTPRD gene associated with blood pressure response to atenolol and resistant hypertension., J Hypertens
Jacob et al., 1996, Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle., Metab. Clin. Exp.
Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Schneider et al., 2005, Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs., Eur. J. Pharmacol.
Ridley et al., 2004, Lidoflazine is a high affinity blocker of the HERG K(+)channel., J. Mol. Cell. Cardiol.
Shimizu et al., 2005, Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome., Curr. Pharm. Des.
Duan et al., 2007, Verapamil blocks HERG channel by the helix residue Y652 and F656 in the S6 transmembrane domain., Acta Pharmacol. Sin.
Cheng et al., Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval., J Pharmacol Toxicol Methods
Nesi G et al., 2014, SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity., Eur J Med Chem
Gu X et al., 2012, Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors., Eur J Med Chem
Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod
Liu XL et al., 2008, Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein., Bioorg Med Chem
Collett et al., 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2., J. Pharmacol. Exp. Ther.
Tang X et al., 2012, Synthesis and evaluation of nitric oxide-releasing DDB derivatives as potential Pgp-mediated MDR reversal agents in MCF-7/Adr cells., Bioorg Med Chem Lett
Chae SW et al., 2015, Xanthone analogues as potent modulators of intestinal P-glycoprotein., Eur J Med Chem
Silva GL et al., 2001, Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei., J Nat Prod
Gu X et al., 2012, Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors., Bioorg Med Chem
Lou K et al., 2014, Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies., J Med Chem
Liu J et al., 2013, 20(S)-Protopanaxadiol (PPD) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs., Bioorg Med Chem
Colabufo NA et al., 2008, Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents., J Med Chem
Perestelo NR et al., 2011, Overcoming human P-glycoprotein-dependent multidrug resistance with novel dihydro-β-agarofuran sesquiterpenes., Eur J Med Chem
Nievergelt A et al., 2010, Identification of serotonin 5-HT1A receptor partial agonists in ginger., Bioorg Med Chem
Mickisch et al., 1991, Transgenic mice that express the human multidrug-resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance., Proc. Natl. Acad. Sci. U.S.A.
Walz et al., 1989, Similar effects of cyclosporine and verapamil on lymphokine, interleukin 2 receptor, and proto-oncogene expression., Transplantation
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Liu et al., 2003, Calmodulin is involved in heat shock signal transduction in wheat., Plant Physiol.
Chang SW et al., 2018, Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes., Pharmacogenomics J
Vandell AG et al., 2012, G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension., Hypertension
Zhao Q et al., 2008, Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population., Pharmacogenet Genomics
Beitelshees AL et al., 2007, KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)., Pharmacogenet Genomics
Nielsen T et al., 2008, The KCNMB1 Glu65Lys polymorphism associates with reduced systolic and diastolic blood pressure in the Inter99 study of 5729 Danes., J Hypertens
Dobrev D et al., 1999, The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum., Br J Pharmacol
Perrotton T et al., 2007, (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1., J Biol Chem
Wong IL et al., 2009, Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives., J Med Chem
Price ET et al., 2011, Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study., Pharmacogenet Genomics
Block et al., 1993, Transcriptional activation of low density lipoprotein receptor gene by angiotensin-converting enzyme inhibitors and Ca(2+)-channel blockers involves protein kinase C isoforms., Proc. Natl. Acad. Sci. U.S.A.
Takemura et al., 1992, Effect of verapamil on the class I major histocompatibility complex antigen expression in K562 chronic myelogenous leukemia cells treated with recombinant human interferon-gamma., Cancer Lett.
Tsukamoto et al., 1987, Effect of calcium channel blockers and trifluoperazine on rat liver regeneration., Eur. J. Pharmacol.
Perez-Reyes et al., 2009, Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs., J. Pharmacol. Exp. Ther.
Shibata K et al., 1998, Effects of quinidine and verapamil on human cardiovascular alpha1-adrenoceptors., Circulation

VERAPAMIL KCNMB1

Interaction Score: 4.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18496125 17700361 18854753

Sources:
PharmGKB
VERAPAMIL KCNIP1

Interaction Score: 4.54

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18496125 17700361 18854753

Sources:
PharmGKB
VERAPAMIL TPCN1

Interaction Score: 1.14

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
VERAPAMIL PLEKHH2

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27670767

Sources:
PharmGKB
VERAPAMIL TPCN2

Interaction Score: 1.14

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology
VERAPAMIL GRK4

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22949529

Sources:
PharmGKB
VERAPAMIL NALCN

Interaction Score: 0.57

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
VERAPAMIL PTPRD

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26425837

Sources:
PharmGKB
VERAPAMIL NOS1AP

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19247217

Sources:
PharmGKB
VERAPAMIL KCNA4

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18604993

Sources:
NCI
VERAPAMIL KCNJ5

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Na-Ca chanel blocker

Alteration KCNJ5:L168R

PMIDs:
None found

Sources:
CGI
VERAPAMIL CACNA1G

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
16699084 21149638 19125880 11752352

Sources:
TEND TTD DrugBank
VERAPAMIL CACNB3

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial
VERAPAMIL CACNB4

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial
VERAPAMIL CACNB1

Interaction Score: 0.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial
VERAPAMIL CACNA1A

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
19125880 10385261

Sources:
DrugBank
VERAPAMIL CACNA1C

Interaction Score: 0.2

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? True

PMIDs:
15880143 19125880 9846638 20031608 15286207

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology
VERAPAMIL CACNB2

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Verapamil,Calan, Covera-HS

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial
VERAPAMIL KCNJ11

Interaction Score: 0.18

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11752352 12883317 17409272 17038430

Sources:
DrugBank
VERAPAMIL KCNA10

Interaction Score: 0.16

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
VERAPAMIL KCNA7

Interaction Score: 0.14

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand None

PMIDs:
None found

Sources:
GuideToPharmacology
VERAPAMIL CACNA1D

Interaction Score: 0.13

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? False

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial GuideToPharmacology
VERAPAMIL CACNA1I

Interaction Score: 0.13

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
17139284 17016423

Sources:
TEND
VERAPAMIL CACNA1F

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial
VERAPAMIL CACNA1S

Interaction Score: 0.11

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Antagonist

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial GuideToPharmacology
VERAPAMIL LDLR

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7683421

Sources:
NCI
VERAPAMIL CACNA1B

Interaction Score: 0.11

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
19125880 10385261

Sources:
DrugBank
VERAPAMIL SLC29A4

Interaction Score: 0.1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
VERAPAMIL NR1H3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21562465

Sources:
PharmGKB
VERAPAMIL IL2RA

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2645720

Sources:
NCI
VERAPAMIL ABCB1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24607999 22405646 21348461 17964170 9862768 22209486 25686592 11754602 22429509 24992153 23683834 18257545 21856049 20363635 1671173

Sources:
NCI DTC
VERAPAMIL HSPA4

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12857801

Sources:
NCI
VERAPAMIL ABCC1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17646169 19725578

Sources:
DTC
VERAPAMIL CACNA1H

Interaction Score: 0.06

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
18974361

Sources:
DrugBank
VERAPAMIL MYC

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1511424

Sources:
NCI
VERAPAMIL CACNG1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TEND
VERAPAMIL SLC2A4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8622594

Sources:
NCI
VERAPAMIL TYMS

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3436366

Sources:
NCI
VERAPAMIL IL1B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2686646

Sources:
NCI
VERAPAMIL BAX

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9354939

Sources:
NCI
VERAPAMIL PLAU

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9579573

Sources:
NCI
VERAPAMIL CXCL8

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2686646

Sources:
NCI
VERAPAMIL GSTP1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3566185

Sources:
NCI
VERAPAMIL SLC6A4

Interaction Score: 0.04

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
2940099 9537821

Sources:
DrugBank
VERAPAMIL ADRA1D

Interaction Score: 0.03

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
9570190

Sources:
DrugBank
VERAPAMIL TGFB1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
NCI
VERAPAMIL KCNH2

Interaction Score: 0.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15814090 19125880 15135665 15892662 17588331 16507347

Sources:
DrugBank
VERAPAMIL ADRA1B

Interaction Score: 0.02

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
9570190

Sources:
DrugBank
VERAPAMIL ADRA1A

Interaction Score: 0.01

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
9570190

Sources:
DrugBank
VERAPAMIL CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Details of the Assay for Interaction Inhibition of testosterone 6β-hydroxylation.

Specific Action of the Ligand Inhibition

Endogenous Drug? False

PMIDs:
21393461 9187528

Sources:
DTC PharmGKB GuideToPharmacology

DrugBank: DB00661

Version: 5.1.7

Alternate Names:

52-53-9 CAS Number

Alti-verapamil - 120mg Drug Brand

Alti-verapamil - 80mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories ace inhibitors and calcium channel blockers

Publications:

Dobrev D et al., 1999, The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum., Br J Pharmacol

Patel et al., 2005, Effect of serum withdrawal on the contribution of L-type calcium channels (CaV1.2) to intracellular Ca2+ responses and chemotaxis in cultured human vascular smooth muscle cells., Br. J. Pharmacol.

Tfelt-Hansen et al., 2009, Verapamil for cluster headache. Clinical pharmacology and possible mode of action., Headache

TdgClinicalTrial: VERAPAMIL
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antihypertensive agent

Drug Class Small Molecule

FDA Approval approved

Publications:
TEND: VERAPAMIL
- Version: 01-August-2011
Alternate Names:

Drug Info:

Year of Approval 1981

Drug Class anti-arrhythmia agents

Publications:

DTC: VERAPAMIL

Version: 02-September-2020

Alternate Names:

CHEMBL6966 ChEMBL Drug ID

Drug Info:

Publications:

Nesi G et al., 2014, SAR study on arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity., Eur J Med Chem

Gu X et al., 2012, Synthesis and biological evaluation of novel bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potent P-glycoprotein inhibitors., Eur J Med Chem

Marks KM et al., 2011, The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes., J Nat Prod

NCI: VERAPAMIL

Version: 14-September-2017

Alternate Names:

C928 NCI drug code

Drug Info:

Publications:

Bacon et al., 1989, Potent and specific inhibition of IL-8-, IL-1 alpha- and IL-1 beta-induced in vitro human lymphocyte migration by calcium channel antagonists., Biochem. Biophys. Res. Commun.

Liu et al., 2003, Calmodulin is involved in heat shock signal transduction in wheat., Plant Physiol.

Collett et al., 1999, Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2., J. Pharmacol. Exp. Ther.

PharmGKB: verapamil

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Chang SW et al., 2018, Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes., Pharmacogenomics J

Zhao Q et al., 2008, Interactions among genetic variants from contractile pathway of vascular smooth muscle cell in essential hypertension susceptibility of Chinese Han population., Pharmacogenet Genomics

Beitelshees AL et al., 2007, KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST)., Pharmacogenet Genomics

TTD: Verapamil
- Version: 2020.06.01
Alternate Names:

D0R0FE TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL6966
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
GuideToPharmacology: 135651305
- Version: 29-September-2020
Alternate Names:

Drug Info:

Publications:
CGI: Verapamil
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Endogenous Drug?	False
Specific Action of the Ligand	Inhibition
Direct Interaction?	False

Trial Name	Verapamil,Calan, Covera-HS
Novel drug target	Established target

Specific Action of the Ligand	Antagonist
Endogenous Drug?	False
Direct Interaction?	True

Details of the Assay for Interaction	Inhibition of testosterone 6β-hydroxylation.
Specific Action of the Ligand	Inhibition
Endogenous Drug?	False

52-53-9	CAS Number
Alti-verapamil - 120mg	Drug Brand
Alti-verapamil - 80mg	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	ace inhibitors and calcium channel blockers

Drug family	Na-Ca chanel blocker
Alteration	KCNJ5:L168R

blocker (inhibitory)
inhibitor (inhibitory)

VERAPAMIL Drug Record

VERAPAMIL chembl:CHEMBL6966 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18496125 17700361 18854753

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18496125 17700361 18854753

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Endogenous Drug? False Specific Action of the Ligand Inhibition Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27670767

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22949529

Sources: PharmGKB

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Specific Action of the Ligand None Endogenous Drug? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26425837

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19247217

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18604993

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info: Drug family Na-Ca chanel blocker Alteration KCNJ5:L168R

PMIDs: None found

Sources: CGI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 16699084 21149638 19125880 11752352

Sources: TEND TTD DrugBank

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TEND TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TEND TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Verapamil,Calan, Covera-HS Novel drug target Established target

PMIDs: 19125880

Sources: TEND TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 19125880 10385261

Sources: DrugBank

Interaction Types & Directionality: blocker (inhibitory) inhibitor (inhibitory)

Interaction Info: Specific Action of the Ligand Antagonist Endogenous Drug? False Direct Interaction? True

PMIDs: 15880143 19125880 9846638 20031608 15286207

Sources: TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Verapamil,Calan, Covera-HS

PMIDs: 19125880

Sources: TEND TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 11752352 12883317 17409272 17038430

Interaction Types & Directionality:

n/a

PMIDs:
18496125 17700361 18854753

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18496125 17700361 18854753

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
27670767

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
22949529

Sources:
PharmGKB

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
26425837

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19247217

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18604993

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family Na-Ca chanel blocker

Alteration KCNJ5:L168R

PMIDs:
None found

Sources:
CGI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
16699084 21149638 19125880 11752352

Sources:
TEND TTD DrugBank

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Verapamil,Calan, Covera-HS

Novel drug target Established target

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
19125880 10385261

Sources:
DrugBank

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? True

PMIDs:
15880143 19125880 9846638 20031608 15286207

Sources:
TEND PharmGKB TdgClinicalTrial DrugBank GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Verapamil,Calan, Covera-HS

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
11752352 12883317 17409272 17038430

Sources:
DrugBank

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Endogenous Drug? False

Specific Action of the Ligand None

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

blocker (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Antagonist

Endogenous Drug? False

Direct Interaction? False

PMIDs:
19125880

Sources:
TEND TdgClinicalTrial GuideToPharmacology

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
17139284 17016423